Shortly after the cystic fibrosis (CF) gene was identified in 1989, the race began to develop a gene therapy for this condition. Major efforts utilized full-length cystic fibrosis transmembrane conductance regulator packaged into adenovirus, adeno-associated virus (AAV), or liposomes and delivered to the airways. The drive to find a treatment for CF based on gene therapy drove the early stages of gene therapy in general, particularly those involving AAV gene therapy. Since general overviews of CF gene therapy have already been published, this review considers specifically the efforts using AAV and is focused on honoring the contributions of Dr. Barrie Carter.
Get full access to this article
View all access options for this article.
References
1.
FullerCM, BenosDJ. CFTR!. Am J Physiol, 1992; 263:C267–C286.
2.
BoucherRC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev, 2002; 54:1359–1371.
3.
BrennanML, SchrijverI. Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. J Mol Diagn, 2016; 18:3–14.
4.
Paul-SmithMC, BellRV, AltonWE, et al.Gene therapy for cystic fibrosis: recent progress and current aims. Expert Opin Orphan Drugs, 2016; 4:649–658.
5.
GriesenbachU, PytelKM, AltonEW. Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther, 2015; 26:266–275.
6.
EganM, FlotteT, AfioneS, et al.Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR. Nature, 1992; 358:581–584.
7.
FlotteTR, AfioneSA, SolowR, et al.Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem, 1993; 268:3781–3790.
8.
FlotteTR, AfioneSA, ConradC, et al.Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A, 1993; 90:10613–10617.
9.
FlotteTR, CarterBJ. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis. Adv Pharmacol, 1997; 40:85–101.
10.
TratschinJ-D, MillerI, SmithM, et al.Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol, 1985; 5:3251–3260.
11.
TratschinJ-D, WestM, SandbankT, et al.A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol, 1984; 4:2072–2081.
12.
WivelNA. Historical perspectives pertaining to the NIH Recombinant DNA Advisory Committee. Hum Gene Ther, 2014; 25:19–24.
CarterBJ, KoczotFJ, GarrisonJ, et al.Separate helper functions provided by adenovirus for adenovirus-associated virus multiplication. Nat New Biol, 1973; 244:71–73.
17.
OwensRA, CarterBJ. In vitro resolution of adeno-associated virus DNA hairpin termini by wild-type Rep protein is inhibited by a dominant-negative mutant of rep. J Virol, 1992; 66:1236–1240.
18.
RedemannBE, MendelsonE, CarterBJ. Adeno-associated virus rep protein synthesis during productive infection. J Virol, 1989; 63:873–882.
19.
TrempeJP, CarterBJ. Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J Virol, 1988; 62:3356–3363.
20.
KoczotFJ, CarterBJ, GaronCF, et al.Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A, 1973; 70:215–219.
21.
WeitzmanMD, KyöstiöS, CarterBJ, et al.Interaction of wild-type and mutant adeno-associated virus (AAV) Rep proteins on AAV hairpin DNA. J Virol, 1996; 70:2440–2448.
22.
FlotteTR, CarterBJ, GugginoWB, et al. Generation of high titers of recombinant AAV vectors. US Patent 5,658,776, 1997.
23.
AitkenML, MossRB, WaltzDA, et al.A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther, 2001; 12:1907–1916.
24.
TrapnellBC, ChuCS, PaakkoPK, et al.Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Natl Acad Sci U S A, 1991; 88:6565–6569.
25.
SirningerJ, MullerC, BraagS, et al.Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther, 2004; 15:832–841.
26.
FischerAC, SmithCI, CebotaruL, et al.Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther, 2007; 15:756–763.
27.
FlotteTR, FischerAC, GoetzmannJ, et al.Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther, 2010; 18:594–600.
28.
DuanDS, SharmaP, YangJS, et al.Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol, 1998; 72:8568–8577.
29.
ConradCK, AllenSS, AfioneSA, et al.Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther, 1996; 3:658–668.
LiangJ, BalachandraS, NgoS, et al.Feedback regulation of steady-state epithelial turnover and organ size. Nature, 2017; 548:588–591.
32.
MingozziF, HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
33.
FaleseL, SandzaK, YatesB, et al.Strategy to detect pre-existing immunity to AAV gene therapy. Gene Ther, 2017; 24:768–778.
34.
BeckSE, JonesLA, ChesnutK, et al.Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol, 1999; 73:9446–9455.
35.
FischerAC, BeckSE, SmithCI, et al.Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther, 2003; 8:918–926.
36.
WagnerJA, ReynoldsT, MoranML, et al.Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet, 1998; 351:1702–1703.
37.
WagnerJA, NepomucenoIB, MessnerAH, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther, 2002; 13:1349–1359.
38.
FlotteTR, ZeitlinPL, ReynoldsTC, et al.Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther, 2003; 14:1079–1088.
39.
MossRB, RodmanD, SpencerLT, et al.Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest, 2004; 125:509–521.
40.
MossRB, MillaC, ColomboJ, et al.Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther, 2007; 18:726–732.
